Direkt zum Inhalt
Merck
  • Optimization of AAV vectors for transactivator-regulated enhanced gene expression within targeted neuronal populations.

Optimization of AAV vectors for transactivator-regulated enhanced gene expression within targeted neuronal populations.

iScience (2024-05-27)
Leo Kojima, Kaoru Seiriki, Hiroki Rokujo, Takanobu Nakazawa, Atsushi Kasai, Hitoshi Hashimoto
ZUSAMMENFASSUNG

Adeno-associated virus (AAV) vectors are potential tools for cell-type-selective gene delivery to the central nervous system. Although cell-type-specific enhancers and promoters have been identified for AAV systems, there is limited information regarding the effects of AAV genomic components on the selectivity and efficiency of gene expression. Here, we offer an alternative strategy to provide specific and efficient gene delivery to a targeted neuronal population by optimizing recombinant AAV genomic components, named TAREGET (TransActivator-Regulated Enhanced Gene Expression within Targeted neuronal populations). We established this strategy in oxytocinergic neurons and showed that the TAREGET enabled sufficient gene expression to label long-projecting axons in wild-type mice. Its application to other cell types, including serotonergic and dopaminergic neurons, was also demonstrated. These results demonstrate that optimization of AAV expression cassettes can improve the specificity and efficiency of cell-type-specific gene expression and that TAREGET can renew previously established cell-type-specific promoters with improved performance.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-Neurophysin-1-Antikörper, Klon PS38, clone PS 38, from mouse